CORDIS
EU research results

CORDIS

English EN

Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies

Project information

Grant agreement ID: 602051

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 922 487,76

  • EU contribution

    € 2 861 500

Coordinated by:

ISTITUTO SUPERIORE DI SANITA

Italy

Objective

Human cystic echinococcosis (CE), one of the most widespread helminthic zoonoses, is a chronic disease caused by infection with the larval stage of the tapeworm Echinococcus granulosus. This disease is highly endemic in some southern (Spain and Italy), eastern (Bulgaria and Romania) European countries and associated (Turkey) countries, where it still represents a major health and economic problem. In endemic areas the annual incidence of CE ranges from 1 to 200 per 100,000 inhabitants and 2-3 million cases are globally estimated. Case series and small clinical trials show a mortality rate of 2-4% for CE, but this increases markedly with substandard treatment and care. The diagnosis of human CE is mainly based on imaging techniques and serological confirmation. Clinical decision making is difficult and the natural history of the cyst is still poorly known. CE is chronic, complex and still neglected. For these reasons the main objectives of HERACLES are:

• Identify by ultrasound screening the population affected by CE in endemic rural areas of CEE countries;
• Create CEE national registries for surveillance of CE;
• Establish a representative bio-bank of genetic Egc isolates and blood/serum/plasma samples;
• Validate new molecular-based POC-LOC kits for immunological surveillance, diagnosis and follow-up;
• Identify factor/s associated with CE response to therapy or lack thereof through investigation of host-parasite interplay (parasite virulence vs human immunity);
• Increase drug bioavailability in an in vivo model, decreasing the length of antiparasitic (ABZ based) treatment of CE and synthesize a new enantiomeric drug based on ABZ.

The project stakeholders, especially the rural populations in which CE is endemic, as well as SMEs, will be engaged as an integral part of the project. Special events to increase general awareness of CE and training activities for local health care providers will be organized.

Coordinator

ISTITUTO SUPERIORE DI SANITA

Address

Viale Regina Elena 299
00161 Roma

Italy

Activity type

Research Organisations

EU Contribution

€ 752 208

Administrative Contact

Rosa Martoccia (Dr.)

Participants (9)

UNIVERSITA DEGLI STUDI DI PAVIA

Italy

EU Contribution

€ 421 230

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 483 092

SPITATUL CLINIC COLENTINA BUCURESTI

Romania

EU Contribution

€ 335 000

HACETTEPE UNIVERSITESI

Turkey

EU Contribution

€ 350 000

"SPECIALIZED HOSPITAL FOR ACTIVE TREATMENT OF INFECTIOUS AND PARASITIC DISEASES ""PROF. I. KIROV'"

Bulgaria

EU Contribution

€ 180 000

MINISTRY OF AGRICULTURE AND FORESTRY

Turkey

ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU

Italy

EU Contribution

€ 125 000

VIRCELL SL

Spain

EU Contribution

€ 119 970

TEKIRDAG NAMIK KEMAL UNIVERSITESI

Turkey

EU Contribution

€ 95 000

Project information

Grant agreement ID: 602051

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 922 487,76

  • EU contribution

    € 2 861 500

Coordinated by:

ISTITUTO SUPERIORE DI SANITA

Italy